Edicotinib

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205972

CAS#: 1142363-52-7 (free)

Description: Edicotinib, also known as JNJ-40346527, is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. FMS tyrosine kinase inhibitor JNJ-40346527 blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS cannot activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tumor cells.


Chemical Structure

img
Edicotinib
CAS# 1142363-52-7 (free)

Theoretical Analysis

MedKoo Cat#: 205972
Name: Edicotinib
CAS#: 1142363-52-7 (free)
Chemical Formula: C27H35N5O2
Exact Mass: 461.2791
Molecular Weight: 461.61
Elemental Analysis: C, 70.25; H, 7.64; N, 15.17; O, 6.93

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-02-24. Prices are subject to change without notice.

Edicotinib is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Related CAS #: 1142363-52-7 (free)   1559069-92-9 (hydrochloride)  

Synonym: JNJ40346527; JNJ 40346527; JNJ-40346527; Edicotinib;

IUPAC/Chemical Name: 4-Cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide

InChi Key: BNVPFDRNGHMRJS-UHFFFAOYSA-N

InChi Code: InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33)

SMILES Code: O=C(C1=NC(C#N)=CN1)NC2=CC=C(C3CC(C)(C)OC(C)(C)C3)N=C2C4=CCC(C)(C)CC4

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 461.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Pass HI, Lavilla C, Canino C, Goparaju C, Preiss J, Noreen S, Blandino G,
Cioce M. Inhibition of the colony-stimulating-factor-1 receptor affects the
resistance of lung cancer cells to cisplatin. Oncotarget. 2016 Jul 28. doi:
10.18632/oncotarget.10895. [Epub ahead of print] PubMed PMID: 27486763.

2: Genovese MC, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, Manthey
CL, Yan XD, Ge T, Franks C, Greenspan A. Results from a Phase IIA Parallel Group
Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active
Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. J
Rheumatol. 2015 Oct;42(10):1752-60. doi: 10.3899/jrheum.141580. Epub 2015 Aug 1.
PubMed PMID: 26233509.

3: von Tresckow B, Morschhauser F, Ribrag V, Topp MS, Chien C, Seetharam S,
Aquino R, Kotoulek S, de Boer CJ, Engert A. An Open-Label, Multicenter, Phase
I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or
Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50. doi:
10.1158/1078-0432.CCR-14-1845. Epub 2015 Jan 27. PubMed PMID: 25628399.



Additional Information